Enhancing Vision to Revitalize Life
The Eyedaptic Solution – Why We Win

... effective full field of vision

... wearable for mobility

... easy to use & visually adaptive

... AR seamless integration

We simulate natural vision to help people return to fuller lives

U.S. FDA Class I Exempt Device
Magnification Alone is Inadequate

Current Low Vision Aids Offering ONLY Magnification, Color and Contrast Adjustments Not Addressing Advanced AMD Sufferers’ Needs

It Drastically Diminishes Field of Vision

Initial Target: Late Stage AMD 10M worldwide

178M AMD sufferers worldwide

400M with retinal disease worldwide

NO Available Treatment for Dry AMD (90% of cases)

Market Landscape

10M worldwide

178M AMD sufferers worldwide

400M with retinal disease worldwide
Why We Uniquely Help Users

We provide the whole picture by both maintaining a Wide Field of View and recovering the Central Field.

Eyedaptic effectively recovers the visual field!
How Our Solution Works

1. Simulated Natural Vision
2. Open Market AR Hardware + Proprietary Software
3. Adaptive Systems
4. Vision w/AMD
5. Image Capture
6. Display
7. 4 Patents pending (+9 Provisionals filed) & FTO completed
User Validation & Pre-Clinical w/ EYE-01

30 Users to Date
73 – 105 Age Range
20/60 – 20/400 Vision
Mostly Dry AMD

- All had central scotomas (vision deficits)
- Some used their peripheral vision (eccentric viewing), but some could not before training protocol
- 3 Users visions 20/60 to 20/80 in the better eye

% increase in reading speed
Trial E1.1 with EYE-01 Prototype: Methods

Visit 1: Baseline assessment and device training

Visit 2 (within 1 week): Quick refresher and features testing

Goals & Endpoints:
- Critical Print size & Reading Acuity
- Independent Daily Living Task Assessment
- Qualitative exploration of Training Program & EYE-01 features

10 Users to Date
79 – 90 Age Range
20/70 – 20/200 Vision
All Dry AMD
A New Timed Instrumental Activities Of Daily Living (TIADL) Measure For Evaluation Of Rehabilitation Outcomes (V.L. Gills¹, M. MacKeben², D.C. Fletcher¹,²)

Timed Independent Activities of Daily Living (TIADLs):
- Reading a bill
- Identifying & Reading Cans
- Sign spotting & reading

EYE-01 @ 3X (n=10)

25% - 50% Improvement
Trial E1.1 w/EYE-01: Clinical Validation of Features

Ability to perform a given task with & without EYE-01

Increased Independence:
- Reading a bill
- Identifying Canned Goods
- Sign spotting & reading

Average 100% Improvement

Successful Task Completion

- Bill
- Cans
- Signs

Without EYE-01
With EYE-01
Trial E1.1 w/EYE-01: Clinical Validation of Features

Quantitative Evaluation of reading ability and visual acuity

MNRead Reading Assessment:
- Critical print size
- Reading Acuity
- Scotoma pattern dependencies

>80% Improvement vs. Baseline

Change from Baseline (letters gained)
Clinical Trials – Summary & Next Steps

Conclusions:

§ EYE-01 Device lead to improved function & increased independence
§ Visual Acuity improvement comparable to Wet AMD & DME drugs
§ Ability for extended use & training facilitates further improvements

Next Steps:

§ E1.2 Expansion study to increase sample size
§ E2 Broader study including take home for extended usage
§ E2 Focus on utility with VFQ (Visual Function Questionnaire)
**In Home Usage**

**Goal:** Assess In Home Useability & UI/UX Robustness

**Method:** Extended data gathering on all modes, motion & time usage

**Early Findings:**
- Mode changes take more advantage of Portal mode, for context, with self training over time.
- Frequency & elapsed time usage increasing over month long trial period.
- Special Features i.e. Britext helpful for point tasks (such as pill bottle reading).
Team

Technology

Jay Cormier
President & CEO
Founder

Dave Watola
Chief Tech Officer
Cofounder

Jerry Fitch
Board Director

Art Reidel
Board Director

Medical

Dr. Mitul Mehta
Chief Medical Officer
Cofounder

Dr. Brian Kim
Medical Advisor
Cofounder

Dr. B. Kuppermann
Retina Advisor

Peter Gluck Esq.
IP Advisor & Patent Council

Orlando Rodrigues
Eye Care Ecosystem Commercial Advisor

Dr. Becky Kammer
Low Vision Advisor

Dr. Paul Karpecki
Optometry Advisor

Jim Cobb
Medical Device Commercial Advisor

Jay Cormier
President & CEO
Founder

Dave Watola
Chief Tech Officer
Cofounder

Jerry Fitch
Board Director

Art Reidel
Board Director

Dr. Mitul Mehta
Chief Medical Officer
Cofounder

Dr. Brian Kim
Medical Advisor
Cofounder

Dr. B. Kuppermann
Retina Advisor

Peter Gluck Esq.
IP Advisor & Patent Council

Orlando Rodrigues
Eye Care Ecosystem Commercial Advisor

Dr. Becky Kammer
Low Vision Advisor

Dr. Paul Karpecki
Optometry Advisor

Jim Cobb
Medical Device Commercial Advisor
The image contains a timeline titled "Key Milestones". It is divided into four sections, each representing a stage of development and fundraising:

1. **Completed 2017**
   - Protos & Core Tech Validated
   - Team Formed
   - $725K raised

2. **1H2018**
   - Patents Filed
   - UI Testing
   - $600K raised

3. **2H2018**
   - Preclinical Data
   - Community Building
   - $1.4M raise

4. **2019**
   - EYE1 Study Data
   - Beta Testing
   - USA Launch
   - $7.5M raise Growth Capital